Investors Alert: Amgen, Inc. (NASDAQ:AMGN), Galena Biopharma Inc (NASDAQ ... Market News Call 18 announced that the company's Phase 3 study (Study 116) evaluating idelalisib in combination with rituximab in previously-treated chronic lymphocytic leukemia (CLL) patients who were not fit for chemotherapy was accepted for presentation during a ... |
